Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 29

    1.

    Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade.

    Lai M, Afdhal NH.

    Am J Gastroenterol. 2011 Dec;106(12):2121-2. doi: 10.1038/ajg.2011.343.

    PMID:
    22138940
    [PubMed - indexed for MEDLINE]
    2.

    Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C.

    Rizzo L, Calvaruso V, Cacopardo B, Alessi N, Attanasio M, Petta S, Fatuzzo F, Montineri A, Mazzola A, L'abbate L, Nunnari G, Bronte F, Di Marco V, Craxì A, Cammà C.

    Am J Gastroenterol. 2011 Dec;106(12):2112-20. doi: 10.1038/ajg.2011.341. Epub 2011 Oct 4.

    PMID:
    21971536
    [PubMed - indexed for MEDLINE]
    3.

    Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer?

    Tamori A, Kawajiri H, Takashima T, Motoyama H, Morikawa H, Enomoto M, Hirakawa K, Kawada N.

    Am J Gastroenterol. 2011 Oct;106(10):1865-6. doi: 10.1038/ajg.2011.258. No abstract available.

    PMID:
    21979218
    [PubMed - indexed for MEDLINE]
    4.

    The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.

    Munteanu M, Ratziu V, Poynard T.

    Am J Gastroenterol. 2011 Oct;106(10):1853; author reply 1853-4. doi: 10.1038/ajg.2011.259. No abstract available.

    PMID:
    21979207
    [PubMed - indexed for MEDLINE]
    5.

    Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

    Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS.

    Am J Gastroenterol. 2012 Jan;107(1):64-74. doi: 10.1038/ajg.2011.312. Epub 2011 Sep 20.

    PMID:
    21931376
    [PubMed - indexed for MEDLINE]
    6.

    Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation.

    Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R.

    Am J Gastroenterol. 2011 Dec;106(12):2123-32. doi: 10.1038/ajg.2011.252. Epub 2011 Aug 9.

    PMID:
    21826113
    [PubMed - indexed for MEDLINE]
    7.

    A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.

    Evon DM, Simpson K, Kixmiller S, Galanko J, Dougherty K, Golin C, Fried MW.

    Am J Gastroenterol. 2011 Oct;106(10):1777-86. doi: 10.1038/ajg.2011.219. Epub 2011 Jul 19.

    PMID:
    21769136
    [PubMed - indexed for MEDLINE]
    8.

    The IL-28B genotype predicts which slow-responding hepatitis C-infected patients will benefit from treatment extension.

    Pearlman BL, Ehleben C.

    Am J Gastroenterol. 2011 Jul;106(7):1370-1. doi: 10.1038/ajg.2011.149. No abstract available.

    PMID:
    21731027
    [PubMed - indexed for MEDLINE]
    9.

    Quality of care for gastrointestinal conditions: a primer for gastroenterologists.

    Kappelman MD, Dorn SD, Peterson E, Runge T, Allen JI.

    Am J Gastroenterol. 2011 Jul;106(7):1182-7. doi: 10.1038/ajg.2011.118. Review.

    PMID:
    21731014
    [PubMed - indexed for MEDLINE]
    10.

    Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin.

    de Rueda PM, López-Nevot MÁ, Sáenz-López P, Casado J, Martín-Casares A, Palomares P, Quiles R, Gila A, Romero-Gómez M, Pavón EJ, Muñoz JA, Carazo A, Sanz-Cameno P, Moreno-Otero R, Diago M, León J, Ruiz-Extremera A, Salmerón J.

    Am J Gastroenterol. 2011 Jul;106(7):1246-54. doi: 10.1038/ajg.2011.82. Epub 2011 Jun 14.

    PMID:
    21670772
    [PubMed - indexed for MEDLINE]
    11.

    Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection.

    Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y, Peveling-Oberhag J, Radeke HH, Sarrazin C, Herrmann E, Zeuzem S, Waidmann O, Piiper A.

    Am J Gastroenterol. 2011 Sep;106(9):1663-9. doi: 10.1038/ajg.2011.161. Epub 2011 May 24.

    PMID:
    21606975
    [PubMed - indexed for MEDLINE]
    12.

    Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan.

    Lai SW, Muo CH, Liao KF, Sung FC, Chen PC.

    Am J Gastroenterol. 2011 Sep;106(9):1697-704. doi: 10.1038/ajg.2011.155. Epub 2011 May 17. Erratum in: Am J Gastroenterol. 2011 Nov;106(11):2053.

    PMID:
    21577242
    [PubMed - indexed for MEDLINE]
    13.

    The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6.

    Seto WK, Tanaka Y, Liu K, Lai CL, Yuen MF.

    Am J Gastroenterol. 2011 May;106(5):1007-8. No abstract available.

    PMID:
    21540909
    [PubMed - indexed for MEDLINE]
    14.

    A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.

    Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J, Leroy V, Fouchard-Hubert I, Bertrais S, Gallois Y, Oberti F, Dib N, Calès P.

    Am J Gastroenterol. 2011 Jul;106(7):1255-63. doi: 10.1038/ajg.2011.100. Epub 2011 Apr 5.

    PMID:
    21468012
    [PubMed - indexed for MEDLINE]
    15.

    Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C.

    Fontana RJ, Sanyal AJ, Ghany MG, Bonkovsky HL, Morgan TR, Litman HJ, Reid AE, Lee WM, Naishadham D; HALT-C Trial Study Group.

    Am J Gastroenterol. 2011 May;106(5):884-93. Epub 2010 Dec 7.

    PMID:
    21139575
    [PubMed - indexed for MEDLINE]
    16.

    Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.

    Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, Mohanty S, Jensen D.

    Am J Gastroenterol. 2011 Mar;106(3):452-8. Epub 2010 Nov 9.

    PMID:
    21063395
    [PubMed - indexed for MEDLINE]
    17.

    Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study.

    Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El-Serag HB.

    Am J Gastroenterol. 2011 Mar;106(3):483-91. Epub 2010 Nov 9.

    PMID:
    21063393
    [PubMed - indexed for MEDLINE]
    18.

    IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.

    Clark PJ, Thompson AJ, McHutchison JG.

    Am J Gastroenterol. 2011 Jan;106(1):38-45. Epub 2010 Oct 5. Review.

    PMID:
    20924369
    [PubMed - indexed for MEDLINE]
    19.

    Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment.

    Noureddin M, Ghany MG.

    Am J Gastroenterol. 2010 Oct;105(10):2174-6.

    PMID:
    20927065
    [PubMed - indexed for MEDLINE]
    20.

    Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.

    Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, Rodriguez-Caravaca G, Bárcena R, Serra MA, Romero-Gómez M, Fernandez I, Garcia-Samaniego J, Fuente J, Solá R, Moreno-Otero R, Planas R; Group for the Assessment of Prevention of Cirrhosis Complications and Virological Response (APREVIR).

    Am J Gastroenterol. 2010 Oct;105(10):2164-72; quiz 2173. Epub 2010 Aug 10. Erratum in: Am J Gastroenterol. 2010 Oct;105(10):2308.

    PMID:
    20700116
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk